LIVIVO - Search results -

Search results

Result 1 - 10 of total 31

Search options

Article ; Online: The management of sexual dysfunction resulting from radiotherapy and androgen deprivation therapy to treat prostate cancer: A comparison of uro-oncology practice according to disease stage.

Kinnaird, William / Kirby, Michael G / Mitra, Anita / Davda, Reena / Jenkins, Valerie / Payne, Heather

International journal of clinical practice

2020 Volume 75, Issue 4, Page(s) e13873

Abstract: Objectives: To establish current uro-oncology practice in the management of sexual dysfunction (SD) following radiotherapy (RT) and/or androgen deprivation therapy (ADT) to treat prostate cancer. To identify differences in approach to the management of ... ...

Abstract	Objectives: To establish current uro-oncology practice in the management of sexual dysfunction (SD) following radiotherapy (RT) and/or androgen deprivation therapy (ADT) to treat prostate cancer. To identify differences in approach to the management of SD according to disease stage. Subjects and methods: A 14-question mixed methods survey was designed to assess the current UK practice. Closed- and open-ended questions were used to quantify results while allowing participants to expand on answers. The survey was distributed to members of the British Uro-Oncology Group at the 2019 annual meeting. Results: Surveys were completed by 63 uro-oncologists attending the annual meeting of the British Uro-Oncology Group (response rate 66%). The major issue highlighted was a difference in approach to managing SD according to disease stage. More than half of the participants (56%) said 'advanced stage of disease' was a barrier to discussing SD. Clinicians were less likely to discuss SD, take baseline assessments, refer to a specialist clinic or offer rehabilitation when dealing with patients with advanced disease. Only a minority said that the management of SD was primarily their responsibility (11%). Nearly all clinicians (92%) had access to SD clinics; however, the majority of clinicians did not routinely refer patients. Conclusions: This study shows that men with advanced prostate cancer need better support in managing SD. Patients receiving long-term ADT are less likely to be offered any kind of help or intervention. Specific guidance on managing SD in this cohort may result in improvements in sexual function, emotional well-being, quality of life, mental health and confidence.
MeSH term(s)	Androgen Antagonists/therapeutic use ; Androgens ; Humans ; Male ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/radiotherapy ; Quality of Life ; Sexual Dysfunction, Physiological/etiology ; Sexual Dysfunction, Physiological/therapy
Chemical Substances	Androgen Antagonists ; Androgens
Language	English
Publishing date	2020-12-28
Publishing country	England
Document type	Journal Article
ZDB-ID	1386246-7
ISSN	1742-1241 ; 1368-5031
ISSN (online)	1742-1241
ISSN	1368-5031
DOI	10.1111/ijcp.13873
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.301: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market.

Kloner, Robert A / Goldstein, Irwin / Kirby, Michael G / Parker, John D / Sadovsky, Richard

Sexual medicine reviews

2018 Volume 6, Issue 4, Page(s) 583–594

Abstract: Background: The phosphodiesterase-5 (PDE5) inhibitors that have been available for nearly 20 years are highly effective in treating erectile dysfunction and have been consistently shown to be safe when used according to package insert instructions.: ... ...

Abstract	Background: The phosphodiesterase-5 (PDE5) inhibitors that have been available for nearly 20 years are highly effective in treating erectile dysfunction and have been consistently shown to be safe when used according to package insert instructions. Aim: To review the cardiovascular (CV) safety of PDE5 inhibitors used to treat erectile dysfunction. Methods: PubMed, the Derwent Drug File, and Embase were searched to identify papers published from 1990-2016 presenting CV safety data for PDE5 inhibitors. Outcomes: This narrative review focuses mainly on papers published in the last 10 years with CV safety data for sildenafil, tadalafil, or vardenafil. Results: Similar to earlier studies, newer studies demonstrate that PDE5 inhibitors do not show an increased incidence of serious CV adverse events such as cardiac death or myocardial infarction. There are drug-drug interactions with PDE5 inhibitors that for the most part are now commonly known, and PDE5 inhibitors are generally safe to use with other commonly used drugs including antihypertensive agents. Conclusion: PDE5 inhibitors are a class of drugs that when used appropriately demonstrate a favorable CV safety profile and present some encouraging signals for new CV indications, which will require additional study. Kloner RA, Goldstein I, Kirby MG, et al. Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. Sex Med Rev 2018;6:583-594.
MeSH term(s)	Erectile Dysfunction/drug therapy ; Heart Failure/epidemiology ; Humans ; Male ; Myocardial Infarction/epidemiology ; Phosphodiesterase 5 Inhibitors/adverse effects ; Phosphodiesterase 5 Inhibitors/therapeutic use ; Vasodilator Agents/adverse effects ; Vasodilator Agents/therapeutic use
Chemical Substances	Phosphodiesterase 5 Inhibitors ; Vasodilator Agents
Language	English
Publishing date	2018-06-28
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2722257-3
ISSN	2050-0521 ; 2050-0513
ISSN (online)	2050-0521
ISSN	2050-0513
DOI	10.1016/j.sxmr.2018.03.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prescription switching: Rationales and risks.

Kirby, Michael G / Allchorne, Paula / Appanna, Tim / Davey, Patrick / Gledhill, Richard / Green, James S A / Greene, Damian / Rosario, Derek J

International journal of clinical practice

2019 Volume 74, Issue 1, Page(s) e13429

Abstract: Background: Therapeutic drug switching is commonplace across a broad range of indications and, within a drug class, is often facilitated by the availability of multiple drugs considered equivalent. Such treatment changes are often considered to improve ... ...

Abstract	Background: Therapeutic drug switching is commonplace across a broad range of indications and, within a drug class, is often facilitated by the availability of multiple drugs considered equivalent. Such treatment changes are often considered to improve outcomes via better efficacy or fewer side effects, or to be more cost-effective. Drug switching can be both appropriate and beneficial for several reasons; however, switching can also be associated with negative consequences. Aim: To consider the impact of switching in two situations: the use of statins as a well-studied example of within-class drug switching, and gonadotropin-releasing hormone (GnRH)-targeting drug switching as an example of cross-class switching. Results: With the example of statins, within-class switching may be justified to reduce side effects, although the decision to switch is often also driven by the lower cost of generic formulations. With the example of GnRH agonists/antagonists, switching often occurs without the realisation that these drugs belong to different classes, with potential clinical implications. Conclusion: Lessons emerging from these examples will help inform healthcare practitioners who may be considering switching drug prescriptions.
MeSH term(s)	Drug Prescriptions ; Drug Substitution/adverse effects ; Drug Substitution/economics ; Drugs, Generic ; Gonadotropin-Releasing Hormone/agonists ; Gonadotropin-Releasing Hormone/antagonists & inhibitors ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/economics ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
Chemical Substances	Drugs, Generic ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Gonadotropin-Releasing Hormone (33515-09-2)
Language	English
Publishing date	2019-10-07
Publishing country	England
Document type	Journal Article
ZDB-ID	1386246-7
ISSN	1742-1241 ; 1368-5031
ISSN (online)	1742-1241
ISSN	1368-5031
DOI	10.1111/ijcp.13429
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.301: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.

Kloner, Robert A / Goggin, Paul / Goldstein, Irwin / Hackett, Geoffrey / Kirby, Michael G / Osterloh, Ian / Parker, John D / Sadovsky, Richard

Journal of cardiovascular pharmacology and therapeutics

2018 Volume 23, Issue 5, Page(s) 375–386

Abstract: Background: Nitrates and nitrate-containing compounds are vasodilators used for the treatment of angina and heart failure. Phosphodiesterase type 5 inhibitors used for the treatment of erectile dysfunction are also vasodilators, and when taken together ... ...

Abstract	Background: Nitrates and nitrate-containing compounds are vasodilators used for the treatment of angina and heart failure. Phosphodiesterase type 5 inhibitors used for the treatment of erectile dysfunction are also vasodilators, and when taken together with nitrates, synergistic effects that enhance hypotensive effects may occur. Phosphodiesterase type 5 inhibitors are therefore contraindicated in patients taking organic nitrates. Methods and results: A literature review was performed to provide a historical overview of different phosphodiesterase type 5 inhibitors and nitrates and their interaction. The pharmacologic characteristics of phosphodiesterase type 5 inhibitors and nitrates are reviewed, and clinical recommendations for treating cardiovascular disease in men taking phosphodiesterase type 5 inhibitors are discussed. Pharmacologic and adverse drug reactions between nitrates and phosphodiesterase type 5 inhibitors are dependent on many variables. Organic nitrates remain an absolute contraindication in men treated with phosphodiesterase type 5 inhibitors. In general, nitrates may be taken 24 hours after the last dose of short-acting phosphodiesterase type 5 inhibitors and 48 hours after the last dose of long-acting phosphodiesterase type 5 inhibitors. Conclusions: This literature review determined that the use of phosphodiesterase type 5 inhibitors with nitrates is a contraindication, with the duration between the last dose of phosphodiesterase inhibitor and nitrate use generally varying between short- and long-acting phosphodiesterase type 5 formulations. Patients receiving nitrates who wish to use phosphodiesterase type 5 inhibitors should be educated regarding the interaction and should be evaluated to determine whether nitrate treatment can be discontinued. Further research is needed to determine how soon phosphodiesterase type 5 inhibitors can be restarted after a patient has taken a nitrate and the effect of high and low phosphodiesterase type 5 inhibitor doses on the interaction effect.
MeSH term(s)	Angina Pectoris/drug therapy ; Angina Pectoris/physiopathology ; Animals ; Blood Pressure/drug effects ; Contraindications, Drug ; Drug Interactions ; Erectile Dysfunction/diagnosis ; Erectile Dysfunction/drug therapy ; Erectile Dysfunction/physiopathology ; Heart Failure/diagnosis ; Heart Failure/drug therapy ; Heart Failure/physiopathology ; Humans ; Hypotension/chemically induced ; Hypotension/diagnosis ; Hypotension/physiopathology ; Male ; Nitrates/administration & dosage ; Nitrates/adverse effects ; Phosphodiesterase 5 Inhibitors/administration & dosage ; Phosphodiesterase 5 Inhibitors/adverse effects ; Risk Assessment ; Risk Factors ; Treatment Outcome ; Vasodilator Agents/administration & dosage ; Vasodilator Agents/adverse effects
Chemical Substances	Nitrates ; Phosphodiesterase 5 Inhibitors ; Vasodilator Agents
Language	English
Publishing date	2018-05-08
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1329372-2
ISSN	1940-4034 ; 1074-2484
ISSN (online)	1940-4034
ISSN	1074-2484
DOI	10.1177/1074248418771896
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4895: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes.

Taylor, David G / Giuliano, Francois / Hackett, Geoff / Hermes-DeSantis, Evelyn / Kirby, Michael G / Kloner, Robert A / Maguire, Terry / Stecher, Vera / Goggin, Paul

Research in social & administrative pharmacy : RSAP

2018 Volume 15, Issue 5, Page(s) 591–599

Abstract: Erectile dysfunction (ED), which worldwide is likely to affect in excess of 300 million men by 2025, is often either untreated or insufficiently treated. It can be a prelude to other serious illnesses and may be a cause or consequence of depression in ... ...

Abstract	Erectile dysfunction (ED), which worldwide is likely to affect in excess of 300 million men by 2025, is often either untreated or insufficiently treated. It can be a prelude to other serious illnesses and may be a cause or consequence of depression in affected individuals. Among men younger than 60 years of age, ED can be a robust early-stage indicator of vascular disease and type 2 diabetes. Untreated or inadequately treated ED can also be a sign of poor communication between health professionals and service users of all ages. Improved treatment of ED could cost-effectively prevent premature deaths and avoidable morbidity. The extension of community pharmacy‒based health care would enable more men living with ED to safely access effective medications, along with appropriate diagnostic services and support for beneficial lifestyle changes such as smoking cessation in conveniently accessible settings. The task of introducing improved methods of affordably addressing problems linked to ED exemplifies the strategic challenges now facing health care systems globally. Promoting professionally supported self-care in pharmacies has the potential to meet the needs of aging populations in progressively more effective ways.
MeSH term(s)	Cardiovascular Diseases ; Erectile Dysfunction/drug therapy ; Humans ; Male ; Pharmacists/organization & administration ; Professional Role ; Public Policy ; Self Care
Language	English
Publishing date	2018-07-21
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2192059-X
ISSN	1934-8150 ; 1551-7411
ISSN (online)	1934-8150
ISSN	1551-7411
DOI	10.1016/j.sapharm.2018.07.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Diabetes and the urologist: a growing problem.

Goldstraw, Miles A / Kirby, Michael G / Bhardwa, Jeetesh / Kirby, Roger S

BJU international

2007 Volume 99, Issue 3, Page(s) 513–517

Abstract: The incidence of diabetes continues to increase dramatically; this incidence is predominantly of the type-2 form which clusters together with other comorbidities of hypertension and lipid abnormalities, to form the metabolic syndrome. These conditions ... ...

Abstract	The incidence of diabetes continues to increase dramatically; this incidence is predominantly of the type-2 form which clusters together with other comorbidities of hypertension and lipid abnormalities, to form the metabolic syndrome. These conditions will have an increasing impact on urological practice, with erectile dysfunction, hypogonadism, voiding difficulties and urinary tract infections all more common in these patients. These symptoms might be the initial presentation of previously undiagnosed diabetes and it is important to recognise this condition early to avoid later complications including end-stage renal failure.
MeSH term(s)	Adult ; Aged ; Diabetes Complications/epidemiology ; Diabetes Complications/etiology ; Diabetes Complications/prevention & control ; Diabetes Mellitus/diagnosis ; Diabetes Mellitus/epidemiology ; Female ; Female Urogenital Diseases/epidemiology ; Female Urogenital Diseases/etiology ; Female Urogenital Diseases/prevention & control ; Humans ; Incidence ; Male ; Male Urogenital Diseases/epidemiology ; Male Urogenital Diseases/etiology ; Male Urogenital Diseases/prevention & control ; Middle Aged
Language	English
Publishing date	2007-03
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1462191-5
ISSN	1464-410X ; 1464-4096 ; 1358-8672
ISSN (online)	1464-410X
ISSN	1464-4096 ; 1358-8672
DOI	10.1111/j.1464-410X.2006.06588.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.107: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 13: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book: Early action on agricultural trade reform

Kirby, Michael G

application and effects ; project 11336

(Discussion paper : Bureau of Agricultural and Resource Economics ; 88,3)

1988

Author's details	Michael G. Kirby
Series title	Discussion paper : Bureau of Agricultural and Resource Economics ; 88,3
Keywords	Agrarsubvention ; Handelsliberalisierung ; Wirkungsanalyse ; Welt ; Außenwirtschaftspolitik ; 152535*45
Language	English
Size	VI, 75 S. : graph. Darst
Document type	Book
ISBN	0644082879 ; 9780644082877
Database	ECONomics Information System

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Overactive bladder symptoms and voiding dysfunction in neurologically normal women.

Espuña-Pons, Montserrat / Cardozo, Linda / Chapple, Christopher / Sievert, Karl-Dietrich / van Kerrebroeck, Phillip / Kirby, Michael G

Neurourology and urodynamics

2012 Volume 31, Issue 4, Page(s) 422–428

Abstract: Aims: To understand mechanisms underlying overactive bladder (OAB) and voiding dysfunction (VD) in neurologically normal women.: Methods: Review of MEDLINE from (1982) to (2011) using defined search terms, and manual analysis. Only articles published ...

Abstract	Aims: To understand mechanisms underlying overactive bladder (OAB) and voiding dysfunction (VD) in neurologically normal women. Methods: Review of MEDLINE from (1982) to (2011) using defined search terms, and manual analysis. Only articles published in English were included. Results: One in five women report moderate to severe lower urinary tract symptoms (LUTS). Whilst VD is more common in men, women report a higher rate of storage symptoms or post-micturition symptoms. Post-void residual (PVR) volume measurements are vital in the assessment of women with LUTS and patients with VD without stress incontinence (SUI) are likely to have an elevated PVR (82%). Bladder outlet obstruction (BOO) also causes VD in women and can be alleviated by surgery or alpha-blocker therapy, although OAB symptoms typically remain. Surgical repair for SUI can result in temporary VD in the minority of patients, highlighting the complex interplay that is emerging in the urethral bladder functioning complex in women. Conclusions: Women with impaired bladder emptying present with a wide range of LUTS, and PVR measurement is essential for diagnosis. OAB and VD can clearly coexist and accurate diagnosis of underlying pathophysiology is required. Recommendations for clinical practice and research are provided including: investigation of VD in women with OAB; evaluation of PVR values to determine appropriate therapy and identification of BOO. There is clearly a need for further research into the impact of alpha-blockers in women with VD as well as an evaluation of PVR changes in women with OAB before and after antimuscarinic therapy.
MeSH term(s)	Female ; Humans ; Urinary Bladder Neck Obstruction/complications ; Urinary Bladder Neck Obstruction/diagnosis ; Urinary Bladder Neck Obstruction/physiopathology ; Urinary Bladder, Overactive/complications ; Urinary Bladder, Overactive/diagnosis ; Urinary Bladder, Overactive/physiopathology ; Urination Disorders/complications ; Urination Disorders/diagnosis ; Urination Disorders/physiopathology ; Urodynamics
Language	English
Publishing date	2012-04
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	604904-7
ISSN	1520-6777 ; 0733-2467
ISSN (online)	1520-6777
ISSN	0733-2467
DOI	10.1002/nau.21252
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1828: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Book: Men's health

Farah, Riad N / Kirby, Michael G / Kirby, Roger S

1999

Author's details	ed. by Roger S. Kirby; Michael G. Kirby; Riad N. Farah. Foreword by Donald Acheson
Language	English
Size	XIII, 254 S., Ill., graph. Darst., 24cm
Edition	Repr.
Publisher	Isis Medical Media
Publishing place	Oxford
Document type	Book
Note	Literaturangaben
ISBN	1899066926 ; 9781899066926
Database	Former special subject collection: coastal and deep sea fishing

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: A critical examination of the domestic air transport policy review

Kirby, Michael G

Australian economic papers Vol. 21 , p. 309-320

1982 Volume 21, Page(s) 309–320

Author's details	Michael G. Kirby
Keywords	Luftverkehrspolitik ; Australien
Publisher	Wiley-Blackwell
Publishing place	Richmond, Vic.
Document type	Article
ZDB-ID	207583-0
Database	ECONomics Information System

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED